Gakuubi Martin Muthee, Munusamy Madhaiyan, Liang Zhao-Xun, Ng Siew Bee
Singapore Institute of Food and Biotechnology Innovation (SIFBI), Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, #01-02 Nanos, Singapore 138669, Singapore.
School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.
J Fungi (Basel). 2021 Sep 22;7(10):786. doi: 10.3390/jof7100786.
For years, fungi have served as repositories of bioactive secondary metabolites that form the backbone of many existing drugs. With the global rise in infections associated with antimicrobial resistance, in addition to the growing burden of non-communicable disease, such as cancer, diabetes and cardiovascular ailments, the demand for new drugs that can provide an improved therapeutic outcome has become the utmost priority. The exploration of microbes from understudied and specialized niches is one of the promising ways of discovering promising lead molecules for drug discovery. In recent years, a special class of plant-associated fungi, namely, fungal endophytes, have emerged as an important source of bioactive compounds with unique chemistry and interesting biological activities. The present review focuses on endophytic fungi and their classification, rationale for selection and prioritization of host plants for fungal isolation and examples of strategies that have been adopted to induce the activation of cryptic biosynthetic gene clusters to enhance the biosynthetic potential of fungal endophytes.
多年来,真菌一直是生物活性次生代谢产物的储存库,这些次生代谢产物构成了许多现有药物的基础。随着全球与抗菌药物耐药性相关感染的增加,以及癌症、糖尿病和心血管疾病等非传染性疾病负担的不断加重,对能够提供更好治疗效果的新药的需求已成为当务之急。从研究不足和特殊生态位中探索微生物是发现有前景的药物研发先导分子的一种有前途的方法。近年来,一类特殊的与植物相关的真菌,即内生真菌,已成为具有独特化学性质和有趣生物活性的生物活性化合物的重要来源。本综述重点关注内生真菌及其分类、选择用于真菌分离的宿主植物的理由和优先级,以及为诱导隐秘生物合成基因簇激活以增强内生真菌生物合成潜力而采用的策略示例。